Background: Early stage CLL is a heterogeneous disease with a prognosis ranging from an overall survival of a few months to two decades. Prognostic markers helping to predict the individual course of CLL are highly warranted. The CLL1 trial was initiated to investigate all major prognostic ...
A study of the prognosis of two series of chronic lymphocytic leukemia (CLL) patients (99 from a retrospective series and 196 from a prospective series) has led us to propose a three-stage classification (A, B, C), requiring only a clinical examination and a haemogram. For stage A patien...
B-cell chronic lymphocytic leukemia (B-CLL) is a clonal lymphoproliferative disorder with a highly variable clinical course and prognosis, which is associated with immune dysregulation, especially in the progressive phase. The leukemic clone may be regulated by inhibitory or growth-promoting signals by...
Relation to respiratory function and prognosis. Amer Rev of Resp Dis. 1967;95(4):556-66. •• Collins PF, Stratton Rebecca J, Marinos E. Nutritional support in chronic obstructive pulmonary disease: a systemic review and meta-analysis. Am J Clin Nutr. 2012;95:1385–95. doi:10.3945/aj...
The study presented here (named “CLL7” trial) was aimed at testing whether chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) would improve the outcome of patients with unfavorable prognosis when administered at an early stage. FCR has been the first regimen to prolong surv...
In CLL, the achievement of CR with MRD negativity has emerged as a major goal to improve the prognosis and to optimize the duration of the treatment. For stage A CLL patients, the objective of the treatment is to achieve a CR with undetectable MRD to possibly eradicate the disease. Based ...
The prognosis for "d'embl茅e" leukemic LS following an ALL treatment is less favorable than ALL prognosis for patients of all ages including children. However, the first remission curve breaks at the 18th month and may form a plateau for about 30% of the patients of all ages. One patient...
prognosisearly stageA risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort ...
Chronic lymphocytic leukemia of B cell-type (B-CLL) is looked upon as the most common form of leukemia in the western hemisphere. The prognosis varies from 6 months to 25 years. Cytoreductive therapy is usually restricted to patients with hemopoietic insufficiency or with progressive lymphomas. A...
prognosisTTFTObjectives To validate the predictive value on time to first treatment (TTFT) of AIPS-E and IPS-E evaluated in an independent cohort of newly diagnosed and non-referred Binet stage A CLL patients enrolled in the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540)....